과제정보
This research was supported by the Korea Drug Development Fund funded by the Ministry of Science and ICT; the Ministry of Trade, Industry, and Energy; and the Ministry of Health and Welfare (RS-2021-DD121345, Korea).
참고문헌
- Organization WHO https://www.who.int/news-room/factsheets/detail/lung-cancer
- Siegel RL, Miller KD, Fuchs HE and Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72, 7-33 https://doi.org/10.3322/caac.21708
- Oberije C, De Ruysscher D, Houben R et al (2015) A validated prediction model for overall survival from stage III non-small cell lung cancer: toward survival prediction for individual patients. Int J Radiat Oncol Biol Phys 92, 935-944 https://doi.org/10.1016/j.ijrobp.2015.02.048
- Bernabe-Caro R, Chen Y, Dowlati A and Eason P (2023) Current and emerging treatment options for patients with relapsed small-cell lung carcinoma: a systematic literature review. Clin Lung Cancer 24, 185-208 https://doi.org/10.1016/j.cllc.2023.01.012
- Mitchell JM, Flight RM and Moseley HNB (2021) Untargeted lipidomics of non-small cell lung carcinoma demonstrates differentially abundant lipid classes in cancer vs. non-cancer tissue. Metabolites 11, 740
- Jin S, Sun Y, Liang X et al (2022) Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduct Target Ther 7, 39
- Sung HJ and Cho JY (2008) Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep 41, 615-625 https://doi.org/10.5483/BMBRep.2008.41.9.615
- Dalton WS and Friend SH (2006) Cancer biomarkers--an invitation to the table. Science 312, 1165-1168 https://doi.org/10.1126/science.1125948
- Yin H and Flynn AD (2016) Drugging membrane protein interactions. Annu Rev Biomed Eng 18, 51-76 https://doi.org/10.1146/annurev-bioeng-092115-025322
- Vogel CL, Cobleigh MA, Tripathy D et al (2023) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 41, 1638-1645 https://doi.org/10.1200/JCO.22.02516
- Boonstra MC, de Geus SW, Prevoo HA et al (2016) Selecting targets for tumor imaging: an overview of cancerassociated membrane proteins. Biomark Cancer 8, 119-133 https://doi.org/10.4137/BIC.S38542
- Karami Fath M, Azami J, Masoudi A et al (2022) Exosomebased strategies for diagnosis and therapy of glioma cancer. Cancer Cell Int 22, 262
- Giustini NP, Jeong AR, Buturla J and Bazhenova L (2020) Advances in treatment of locally advanced or metastatic non-small cell lung cancer: targeted therapy. Clin Chest Med 41, 223-235 https://doi.org/10.1016/j.ccm.2020.02.003
- Cameron PH, Chevet E, Pluquet O, Thomas DY and Bergeron JJ (2009) Calnexin phosphorylation attenuates the release of partially misfolded alpha1-antitrypsin to the secretory pathway. J Biol Chem 284, 34570-34579 https://doi.org/10.1074/jbc.M109.053165
- Okayama A, Miyagi Y, Oshita F et al (2014) Proteomic analysis of proteins related to prognosis of lung adenocarcinoma. J Proteome Res 13, 4686-4694 https://doi.org/10.1021/pr4012969
- Chen Y, Ma D, Wang X et al (2019) Calnexin impairs the antitumor immunity of CD4(+) and CD8(+) T cells. Cancer Immunol Res 7, 123-135 https://doi.org/10.1158/2326-6066.CIR-18-0124
- Kobayashi M, Nagashio R, Jiang SX et al (2015) Calnexin is a novel sero-diagnostic marker for lung cancer. Lung Cancer 90, 342-345 https://doi.org/10.1016/j.lungcan.2015.08.015
- Schrag JD, Bergeron JJ, Li Y et al (2001) The structure of calnexin, an ER chaperone involved in quality control of protein folding. Mol Cell 8, 633-644 https://doi.org/10.1016/S1097-2765(01)00318-5
- Wiest DL, Bhandoola A, Punt J, Kreibich G, McKean D and Singer A (1997) Incomplete endoplasmic reticulum (ER) retention in immature thymocytes as revealed by surface expression of "ER-resident" molecular chaperones. Proc Natl Acad Sci U S A 94, 1884-1889 https://doi.org/10.1073/pnas.94.5.1884
- Li HD, Liu WX and Michalak M (2011) Enhanced clathrin-dependent endocytosis in the absence of calnexin. PLoS One 6, e21678
- Myhill N, Lynes EM, Nanji JA et al (2008) The subcellular distribution of calnexin is mediated by PACS-2. Mol Biol Cell 19, 2777-2788 https://doi.org/10.1091/mbc.e07-10-0995